A Law360 email newsletter dated May 5, 2020, summarizing the impact of the COVID-19 pandemic on the legal and business sectors. Key topics include law firms (Nixon Peabody, Pillsbury) cutting programs and pay, retail bankruptcies (J.Crew, Gold's Gym), and court closures in the US, UK, and EU. The document lists numerous law firms in the sidebar, including 'Epstein Becker Green,' which is a corporate law firm unrelated to Jeffrey Epstein's criminal case.
A Cowen 'Collaborative Insights' financial research report dated February 25, 2019, authored by Chen. The document analyzes the market entry of Cannabidiol (CBD) into mass retail, predicting that the beauty sector (Luxury and Prestige) will adopt it before broadline retailers like Walmart or Target. It details specific moves by Barneys, Neiman Marcus, DSW, and Sephora. The document bears the Bates stamp HOUSE_OVERSIGHT_024885, indicating it was part of a document production to the House Oversight Committee, likely incidental to a larger financial investigation as no specific Epstein-related individuals are mentioned in the text.
This document is page 61 of a 'Cowen Collaborative Insights' report dated February 25, 2019, analyzing private companies in the CBD/hemp industry (Botanica, GenCanna, Highline Wellness, Lazarus Naturals, Lord Jones, and Mary's). While stamped 'HOUSE_OVERSIGHT_024877', indicating it is part of a larger document production (likely related to financial oversight), the page content itself is purely market research and contains no direct references to Jeffrey Epstein or his associates. The sidebar indicates the report was intended for Michael Cella at Cowen.
A Cowen equity research report titled 'Cowen's Collective View of CBD - Ahead of the Curve Series,' dated February 25, 2019. The document analyzes the U.S. CBD market, projecting a $16 billion opportunity by 2025, and discusses consumer trends, scientific understanding, and hemp cultivation. The document bears a House Oversight Committee Bates stamp (HOUSE_OVERSIGHT_024819) and a watermark indicating it was intended for Michael Cella at Cowen.
This document, page 58 from a House Oversight collection, provides a detailed real estate analysis of four major Las Vegas retail centers: Forum Shops at Caesars Palace, The Grand Canal Shoppes, The Shoppes at Palazzo, and Fashion Show Mall. It outlines their development history, size, key tenants, occupancy rates, and financial metrics like sales and rent per square foot. The information suggests the document was created shortly after January 2008 and focuses purely on commercial real estate data.
This document is a "Competitive Retail Rent Survey" for four major shopping centers in Las Vegas: Town Square, Mandalay Place, Crystals at CityCenter, and Miracle Mile Shops. It details property specifics like size, tenants, occupancy rates, and financial data including rental rates and tenant sales per square foot. Although tagged as Epstein-related, the document itself does not contain any mention of Jeffrey Epstein, his associates, or related entities; its identifier 'HOUSE_OVERSIGHT_018799' suggests it is an exhibit from a U.S. House Oversight Committee file.
This document provides a summary of major high-profile retail properties on and near the Las Vegas Strip. It details several large shopping centers, including Town Square Las Vegas, Fashion Show Mall, Forum Shops, and The Grand Canal Shoppes, listing their sizes, anchor stores, and key tenants.
This document is a comparative analysis of five luxury resorts and casinos in Las Vegas: Aria, Bellagio, The Cosmopolitan, Venetian/Pallazzo, and Wynn/Encore. It provides a detailed breakdown of hotel, casino, retail, and entertainment statistics for the year 2014, including owners, revenue figures, and key retail tenants. Although requested in the context of an Epstein-related analysis, the document itself contains no direct mentions of Jeffrey Epstein or his known associates; its relevance may stem from its origin as an exhibit in a U.S. House Oversight Committee investigation, as indicated by the Bates number 'HOUSE_OVERSIGHT_018784'.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity